181
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Characterization of isoniazid incorporation into chitosan-poly(aspartic acid) nanoparticles

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 190-199 | Received 18 Aug 2022, Accepted 04 Nov 2022, Published online: 16 Nov 2022
 

Abstract

The incorporation of the drug Isoniazid (an anti-tuberculosis drug) into nanoparticles of polyelectrolyte chitosan-poly(aspartic acid) complexes was carried out by the ionotropic gelation technique, adding a sodium polyaspartate solution containing the drug to a chitosan solution in different proportions in a mass ratio (mg/mg) Isoniazid/Chitosan. This was confirmed by MALDI-TOF/MS, ESI/MS, FTIR, and UV-Vis. The lowest average particle diameter (PD), estimated by DSL, was 148.5 ± 1 nm corresponding to an Isoniazid/chitosan ratio (mg/mg) of 0.5:1. FE-SEM showed nanoparticles in the order of 100–300 nm; whereas AFM showed semi-spherical particle morphology.

Graphical Abstract

Acknowledgments

The authors wish to thank Iván Olortiga, Aurica P. Chiriac, Kevin Tucker, Franco Basile, Rong Zhou, Hugo Alarcón, Alcides López, Silvia Suarez, and Dolores Rivera for their helpful contribution to different aspects of this research.

Author contributions

Carmen L. Zegarra-Urquia: investigation, methodology, conceptualization, formal analysis, and writing—original draft preparation. Julio Santiago: supervision, resources, and writing—original draft preparation. Joel Bumgardner, Alexander Goroncy, and José Vega-Baudrit: formal analysis and writing—original draft preparation. Claudia A. Hernández-Escobar: validation. E. Armando Zaragoza-Contreras: supervision, writing, review, and editing.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.